Flx Case Study

Alzheimer disease (AD) is the most common cause of dementia in the elderly, accounting for 65–70% of all cases (Jellinger, Janetzky, Attems, & Kienzl, 2008). The other dementias are of the Parkinson 's group, the fronto-temporal group and the vascular group. The total worldwide yearly costs for the treatment and care of patients suffering from dementia are estimated to be around 250 billion US dollars. The lifetime risk for AD between the ages of 65 and 100 is 33% for men and 45% for women with an annual increase of 1–2% in the seventh decade to almost 60% in the 10th decade with doubling every 5 years (Jellinger et al., 2008). AD is incurable, and thus represents a major public health problem. AD represents a challenge to humanity due to its relatively recent discovery, progressive nature of the illness, and complex diagnosis.

The disease called Alzheimer’s is the fourth leading cause of death in the United States (Weiner, 1987). It is estimated that the elderly population will double between now and 2030. During this period, the number of elderly will grow by an average of 2.8% annually (U.S. Census Bureau, 2001). By 2050, the number of people with Alzheimer’s is estimated to range from 11.3 million to 16 million (Alzheimer’s Association, 2005). These startling numbers should prompt an examination into one of the leading causes of death among this group of people. Understanding what Alzheimer’s is and the known causes of the disease are a good starting point. For those who have aging family members, knowing the risk factors and warning

“Alzheimer’s disease is the most common type of dementia in elderly people which accounts for 60 to 80 percent of cases (Krishnan, D. S.)”. World Health Organization indicated that Alzheimer’s disease is the “6th leading cause of death in the

Alzheimer’s disease is a prominent brain disease that effects a massive amount of individuals in the United States. Alzheimer’s disease (AD) is the sixth leading cause of death in the United States, accounting for 60-80% of dementia cases, with no chance of being cured, prevented or decelerating over time (Alzheimer’s Association, 2014). AD is the most well-known form of dementia, causing complications in brain function in the areas of memory, thinking, and behavior (Alzheimer’s Association, 2014). In an effort to gain a deeper understanding of Alzheimer’s disease, researchers create new knowledge about the disease, which is then distributed to the public. The goal in this information disbursement is to find new and inventive ways to treat AD, prevent AD from progressing at such a rapid pace, and aid in the quality of life in those diagnosed with AD as well as caregivers and medical professionals providing treatment to individuals’ with AD.

Alzheimer’s disease is a complex illness that affects the brain tissue directly and undergoes gradual memory and behavioral changes which makes it difficult to diagnose. It is known to be the most common form of dementia and is irreversible. Over four million older Americans have Alzheimer’s, and that number is expected to triple in the next twenty years as more people live into their eighties and nineties. (Johnson, 1989). There is still no cure for Alzheimer’s but throughout the past few years a lot of progress has been made.

According to the Alzheimer’s Disease International (ADI), dementia is one of the most prevalent disorders found among

Alzheimer’s disease (AD) is a progressive and fatal form of dementia, frequently seen in the elderly altering their cognition, thought process and behavior. AD is reported in about half of patients that have a dementia diagnosis; one study states that about 10.3% of the population over 65 years is affected by dementia with an increase to almost 50% over the age of 8 (Beattie, 2002). Alzheimer’s disease is not a normal part of the aging process in humans, but rather found in a group of diseases that affect the brain leading to a decline in mental and physical control. AD when diagnosed has a very slow and gradual course, initially affecting the individual’s short term memory (Beattie, 2002). Alzheimer’s disease is the 6th leading cause of death, affecting more than five million people in the United States and is also one of the most common forms of dementia. Dementia can be defined as a disorder of progressive cognitive impairment severe enough to affect daily functions of an individual’s life (Fillit, et al., 2002).

Alzheimer’s disease (AD) is the most common form of dementia known today. The term “dementia” refers to a variety of conditions that arise from the loss of nerve cell function and/or nerve cell death in the brain, including Alzheimer’s disease, vascular dementia, Parkinson’s disease, Creutzfeldt-Jakob disease and other types of mixed dementia. Although all types of dementia arise from neuronal damage and/or death, each form of dementia is associated with distinct brain abnormalities and symptom patterns. Once a patient has been diagnosed with dementia, a physician must conduct further tests in order to determine the exact form of dementia that is present. Recent research indicates that many individuals,

Although Alzheimer’s Disease (AD) is the most widely known cause of dementia in the elderly population, there are many other explanations and clinical diagnoses that

Alzheimer’s disease (AD) is a form of dementia that causes problems with memory, thinking, and behavior. AD typically involves the development of a progressive neuropsychiatric disorder that is characterized by gradual memory impairment, loss of acquired skills and emotional disturbances (Lee, Y. J., Han, S. B., Nam, S. Y., Oh, K. W., & Hong, J. T.). Every 67 seconds an individual in the United States develops AD. AD is the sixth leading cause of death in the United States. There are 5.3 million Americans diagnosed with AD (Latest Alzheimer's Facts and Figures). AD is one of the few degenerative diseases that cannot be prevented, stopped, or cured (Latest Alzheimer's Facts and Figures). Post-mortem examination of the brain of AD patients usually

There is no cure for Alzheimer’s. But drug and non-drug treatments may help with both cognitive and behavioral symptoms

Alzheimer’s disease (AD) is a severe, incurable form of dementia that causes impairment and cognitive deficits such as language, speech, memory and basic motor skills (Buckley, 2011). Currently in the United States, there are 5.2 million individuals living with AD (Alzheimer’s Association, 2013). AD is a deterioration of one’s cognitive functions that prevents the ability for daily function and unfortunately has no known cure or preventative methods (Buckley, 2011).The main deficit that AD has on the brain is the deterioration of different areas of the brain. Not only does a physical toll contribute to patients with AD, but there is also a social stigma that impedes on the normal daily function of life. In this literature review, I will

Alzheimer's is a progressive brain disorder that damages and eventually destroys brain cells affecting memory, changes in thinking, and other mental functions. In addition, it is the most common form of dementia and generally develops slowly and gradually gets worse as brain function declines and cells start to degenerate and die (4). In 1906, Alois Alzheimer, a German physician noticed psychological changes in some individuals so he further observed their brains during an autopsy and noticed a significant difference in brain size along with abnormal deposits in the brain tissue (1). Today Alzheimer’s is considered an epidemic, but is spreading rapidly on a global scale making it a global problem too (2). Unfortunately, Alzheimer's is fatal,

Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. In most people with Alzheimer’s, symptoms first appear in their mid-60s (nih.gov). AD is a multifactorial and progressive neurodegenerative disease. Parts of AD, for example, increased oxidative state, amyloid plaque deposition, and neurofibrillary tangle of tau protein in the central cortex the limbic system of the brain, have been related with Alzheimer's disease. AD standouts amongst the most well-known and feared diseases burdening the elderly community. The disease was once thought to be a natural part of aging, is an extremely incapacitating type of mental dementia.

It is well-established that AD is characterized by amyloid-β plaques; in in vitro studies, TNF-α has been shown to increase the expression of amyloid-β precursor protein and Aβ, components of the extracellular aggregates, in glial and immune cells (Cunningham et al., 2009). Together with the fact that TNF-α induces glutamate-mediated neurotoxicity, it’s apparent that TNF-α plays a pivotal role in the development of AD pathology. Therefore, in regards to the treatment of AD, Jing et al. (2015)’s study is of significant importance as it provides further in vivo evidence that implicates TNF-α and the glutamatergic pathway as potential targets for therapeutical